Navigation Links
PharmAthene Reports Year-End 2009 Financial and Operational Results and Provides Update On Ongoing Litigation With SIGA Technologies
Date:3/23/2010

Accumulated other comprehensive income 1,188,156 386,351 Accumulated deficit (156,310,642) (123,817,664) ----------- ----------- Total stockholders' equity 1,884,364 18,963,439 ----------- ----------- Total liabilities and stockholders' equity $34,065,014 $56,391,270 =========== ===========
    
    
                               PHARMATHENE, INC.
                     CONSOLIDATED STATEMENTS OF OPERATIONS
    
                                              Year ended December 31,
                                              -----------------------
                                               2009           2008
                                               ----           ----
    
    Contract revenue                       $27,549,978     $32,821,526
    Other revenue                                    -          89,802
                                            ----------      ----------
                                            27,549,978      32,911,328
     Operating expenses:
       Research and development             30,219,758      31,812,431
       General and administrative           22,432,585      19,397,532
       Acquired in-process research
        and development                              -      16,131,002
       Depreciation and amortization           872,304         813,891
                                            ----------      ----------
    
    Total operating expenses                53,524,647      68,154,856
                                            ----------      ----------
    
    Loss from operations                   (25,974,669)    (35,243,528)
    Other income (expenses):
       Interest income
'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. PharmAthene to Provide Update on SparVax(TM) Contract Modification Suspension During Year-End 2009 Financial and Operational Results Conference Call on Tuesday March 23, 2010
2. PharmAthene to Host Year-End 2009 Earnings Conference Call and Webcast on Tuesday, March 23, 2010
3. PharmAthene to Present at the 2010 Roth Capital Markets Growth Stock Conference on Monday, March 15, 2010
4. PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine
5. PharmAthene Appoints Jeffrey W. Runge, M.D. to the Companys Board of Directors
6. PharmAthene Announces Updated Time for Conference Call to Review BARDA rPA Decision
7. PharmAthene Reports Third Quarter 2009 Financial and Operational Results
8. PharmAthene Executives Featured in Anthrax Pathogen Training Video for U.S. Department of Homeland Security
9. PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference
10. PharmAthene to Present at the Rodman and Renshaw Annual Global Investment Conference September 10, 2009
11. PharmAthene Reports Second Quarter 2009 Financial and Operational Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 , Not ... in, into or from any jurisdiction where to do so ... jurisdiction.  Shire plc ("Shire" or the "Company") (LSE: ... this afternoon.  Shire confirms it has held a meeting with ... by Shire without the prior agreement or approval of AbbVie. ...
(Date:7/11/2014)... , July 11, 2014  Researchers have pioneered ... images. The new technology, called Virtual Finger, allows ... structures like neurons and synapses using the flat ... technology makes 3D imaging studies orders of magnitude ... an unprecedented level across many areas of experimental ...
(Date:7/10/2014)... Understanding the need for better quality and higher ... that currently exists in this area, ChanTest has recently ... validated ion channel and GPCR cell lines. ChanTest’s ... channels control many critical physiological functions throughout the body. ... to treat a variety of human diseases. , ...
(Date:7/10/2014)... 10, 2014 EvoDerma ’s NOOME Anti-Aging ... rejuvenating device now comes with a second treatment cup to ... , The new cup is thinner on the edges for ... target rough, thin and uneven surfaces on the face, neck ... a stimulating treatment on areas such as the cheeks and ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2
... NEW YORK, Sept. 8 /PRNewswire-Asia-FirstCall/ ... ("the Company" or "AOBO"), a pharmaceutical,company dedicated to improving ... range of prescription and over the counter ("OTC"),products, today ... -- Morgan Stanley Healthcare Corporate Day, ...
... , RICHMOND, Calif., Sept. 8 /PRNewswire-FirstCall/ -- ... (ZFNs) designed by Sangamo BioSciences, Inc., (Nasdaq: SGMO ... embryonic stem cells (hESCs) and induced pluripotent stem cells (hiPSCs). ... and development. Scientists also hope to use these cells ...
... , SAN DIEGO, Sept. 8 ... today announced several key appointments that will expand the breadth of ... the company for continued rapid growth in the development and commercialization ... , , Martin Latterich, Ph.D., has ...
Cached Biology Technology:American Oriental Bioengineering Announces September Investor Conferences Participation 2Sangamo's Zinc Finger Nuclease Technology Used to Efficiently Modify Human Stem Cells 2Sangamo's Zinc Finger Nuclease Technology Used to Efficiently Modify Human Stem Cells 3Sangamo's Zinc Finger Nuclease Technology Used to Efficiently Modify Human Stem Cells 4Biomatrica Makes Several Key Appointments as Part of Continued Growth Plan 2Biomatrica Makes Several Key Appointments as Part of Continued Growth Plan 3Biomatrica Makes Several Key Appointments as Part of Continued Growth Plan 4Biomatrica Makes Several Key Appointments as Part of Continued Growth Plan 5
(Date:7/11/2014)... The increased risk of kidney injury related to the ... the mass of HES molecules, according to a report ... the International Anesthesia Research Society (IARS). , The "total ... HES on cultured human renal proximal tubule cells (PTCs), ... colleagues of University Hospital Wrzburg, Austria. Other factorssuch ...
(Date:7/11/2014)... exists that cannabinoid receptor type 1 can ... influx, and reduce neurotransmitter release. However, some ... can increase extracellular Ca2+ influx and increase ... team, Tongji Hospital Affiliated to Tongji Medical ... China used whole cell voltage-clamp and calcium ...
(Date:7/10/2014)... and other major cities in New Mexico, nearly every ... wastewater rather than precious potable water supplies. Across the ... all golf courses receive treated effluent. Reusing the effluent ... golf courses and homeowners alike fertilize their lawns during ... nitrate. A New Mexico State University turfgrass expert has ...
Breaking Biology News(10 mins):In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2'Tailored' water -- the latest in lawn care 2
... (DIYbio) community has grown, so have concerns among media ... DNA and manipulate life. In 2009, for example, ... the popular misconception: "In Attics and Closets, ,Biohackers, Discover ... survey of DIYbio practitioners (DIYers), the Synthetic Biology Project ...
... years ago, mammalian target of rapamycin or mTOR, a ... the antidepressant effects of ketamine, the first rapidly acting ... later, a group at the National Institutes of Mental ... receptor antagonist, also produced rapidly appearing antidepressant effects, similar ...
... APOPKA, FL--Shade nets are widely used in ornamental crop ... and birds. According to a 2011 study from the ... production in the United States occurred under shade or ... growers have begun experimenting with colored, gray, and white ...
Cached Biology News:First-ever survey of Do-It-Yourself Biology community challenges myths 2mTOR: A key brain signaling mechanism for rapidly acting antidepressants 2Shadehouses with photoselective nets featured in study of growing conditions 2
... controlled pre-amplifier suitable for a broad range ... for recording physiological signal such as ECG, ... input for use with a wide range ... include a stimulus artefact clamp to avoid ...
... be used with all 96-well ... stacking of covered plates ... with automated systems ... are available for use with ...
... Two sizes available for use with 96- or 384-well ... 96 for ease of location on 96-tube plates ... the skirt of the plate* Efficient sealing is ... in conjunction with screw or clip-down hot lid thermal ...
... Polystyrene covers can be used ... Ridged covers for stacking of ... covers for use with automated ... ridged and non-ridged, are available ...
Biology Products: